In an industry where no one knows anything, here, finally, was someone who seemed to know something: Ryan Kavanaugh, a spikily red-haired man-child with an impish grin and a uniform of jeans and Converse sneakers who had an uncanny ability to fill a room and an irresistible outlook on how to make money making movies. Not yet 30 when he founded Relativity Media in 2004, he very quickly became not only a power player in Hollywood but the man who might just save it. With a dwindling number of studios putting out ever fewer movies, other than ones featuring name-brand superheroes, Kavanaugh became first a studio financier and then a fresh-faced buyer of textured, mid-budget films. To bankers, Kavanaugh appeared to have cracked the code, having come up with a way to forecast a famously unpredictable business by replacing the vagaries of intuition with the certainties of math. ... Even Hollywood wasn’t used to a pitch this good. Kavanaugh alternately dazzled and baffled — talking fast, scrawling numbers and arrows and lines on whiteboards, projecting spreadsheets. ... Borrowing a tool from Wall Street, he touted his “Monte Carlo model,” a computer program that runs thousands of simulations, as a device that could predict a film’s success far more reliably than even a sophisticated studio executive. Better, Kavanaugh convinced several studios that he could raise more money for them if they gave him access to their guarded “ultimates” numbers showing the historical or projected performance of a film across all platforms (DVD, video-on-demand, etc.) over a number of years.
Until very recently, aging was just a thing that happens, a decay or breakdown, chaotic and impossibly complex, that seems to accelerate only after we’ve reached the age of reproduction. ... from its birth in the early 1990s, the field of geroscience has faced significant impediments. Coming on the heels of centuries of humbug (e.g., Ponce de Leon, crushed dog testicles, Ted Williams’s frozen head), it has had to overcome a near-universal presumption of quackery. It is also an awkward match with contemporary drug research, which is organized around addressing specific maladies. Since aging is a risk factor rather than a disease — in the language of the FDA, it’s never been considered an “indication” — pharmaceutical companies are disincentivized from developing broadly aging-targeted drugs, and foundations tend to reserve their grant money for cancer, Alzheimer’s, and the like. ... For Guarente, watching the boom and bust of resveratrol was as motivating as it was unnerving. He redoubled his own efforts to be the first to bring an anti-aging pill to market, even as he and Sinclair squabbled with Kennedy and Kaeberlein in the press. At times, the interpersonal strife can seem like nothing so much as the professional equivalent of a red Maserati convertible, a time-slowing denial of the ultimate stakes that bind the men: their shared obsession with combating aging, as every one of them gets older.